title: Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.
abstract: OBJECTIVE
  To assess the utility of dynamic contrast-enhanced MRI parameters in the demonstration of early antiangiogenic effects and as prognostic biomarkers in second-line treatment of advanced-stage non-small-cell lung cancer with vatalanib.
  
  
  METHODS
  The transfer constant (K(trans)) and the initial area under the contrast concentration-time curve at 60 s (AUC60) were assessed in 46 patients. Changes were compared with response evaluation from computed tomography imaging and Response Evaluation Criteria In Solid Tumors guidelines.
  
  
  RESULTS
  Statistically significant mean reductions in K(trans) (38.4%; p < 0.0001) and AUC60 (24.9%; p < 0.0001) were found at day 2. After 12 weeks, 16 patients (35%) demonstrated stable disease and 30 (65%) demonstrated progressive disease. No statistically significant differences in day 2 K(trans) and AUC60 reductions between stable disease and progressive disease patients were found.
  
  
  CONCLUSIONS
  Dynamic contrast-enhanced MRI can demonstrate a statistically significant reduction in vascular parameters of non-small-cell lung cancer, but does not predict patient outcome.
authors.affiliation: Department of Diagnostic & Interventional Radiology & Neuroradiology, University Hospital of University Duisburg-Essen, Essen, Germany.
authors.forename: Felix
authors.initials: F
authors.lastname: Nensa
authors.forename: Jörg
authors.initials: J
authors.lastname: Stattaus
authors.forename: Bruno
authors.initials: B
authors.lastname: Morgan
authors.forename: Mark A
authors.initials: MA
authors.lastname: Horsfield
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
authors.forename: Valerie
authors.initials: V
authors.lastname: Gounant
authors.forename: Antoine
authors.initials: A
authors.lastname: Khalil
authors.forename: Katja
authors.initials: K
authors.lastname: Seng
authors.forename: Berthold
authors.initials: B
authors.lastname: Fischer
authors.forename: Heiko
authors.initials: H
authors.lastname: Krissel
authors.forename: Dirk
authors.initials: D
authors.lastname: Laurent
authors.forename: Daniel
authors.initials: D
authors.lastname: Christoph
authors.forename: Wilfried E E
authors.initials: WE
authors.lastname: Eberhardt
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Gauler
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D015415:Biomarkers; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000008:administration & dosage / Q000627:therapeutic use; D004341:Drug Evaluation; D064420:Drug-Related Side Effects and Adverse Reactions / Q000473:pathology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010793:Phthalazines / Q000008:administration & dosage* / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D011859:Radiography
chemical_list: D020533:Angiogenesis Inhibitors; D015415:Biomarkers; D003287:Contrast Media; D010793:Phthalazines; D011725:Pyridines; C404768:vatalanib